Tumour Immunogenicity Induced by Exogenous Interleukins

  • Federica Cavallo
  • Mirella Giovarelli
  • Francesco Novelli
  • Guido Forni
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


The discrepancy between the efficacy of the anti-tumour reactivity induced by pre-immunisation with non-proliferating, derived or mutagenised tumour cells [1–4] and the ephemerality of that elicited during tumour growth is a paradox around which research in tumour immunology has danced for about a hundred years. The rationale behind both old and new attempts at immunotherapy returns to similar issues in an almost circular loop reflecting the persistent elusiveness of sure concepts (Table 1) [5].


Tumour Rejection Mycobacterium Bovis Immune Memory Peripheral Blood Natural Killer Cell Bladder Carci 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Klein G, Sjogren HD, Klein E and Hellstrom KE: Demonstration of host resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960 (20):1561–1572PubMedGoogle Scholar
  2. 2.
    Forni G, Rhim JS, Pickeral DS, Shevach EM and Green I: Antigenicity of carcinogen and viral induced sarcomas in inbred and randombred guinea pigs. J Immunol 1975 (115):204–210PubMedGoogle Scholar
  3. 3.
    Fujiwara H, Aoki H, Yoshida T, Tomita S, Ikegami R and Hamaoka T: Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T-cell activity and its application to the autochthonous tumor system. J Immunol 1984 (133):509–514PubMedGoogle Scholar
  4. 4.
    Boon T: Turn- variants: immunogenic variants obtained by mutagen treatment of tumor cells. Immunol Today 1985 (6):307–311CrossRefGoogle Scholar
  5. 5.
    Forni G: LAK cells in cancer therapy: A critical assessment. EOS 1989 (9):204–207Google Scholar
  6. 6.
    Comoglio PM and Forni G: Molecular basis of the immunogenicity of cell surface tumor antigens. Expl Cell Biol 1974 (44):150–169Google Scholar
  7. 7.
    Cerottini JC and Brunner KT: Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol 1984 (18):67–79CrossRefGoogle Scholar
  8. 8.
    Hewitt HB: Animal tumor models for tumor immunology. J Biol Resp Modif 1982 (1):107–19Google Scholar
  9. 9.
    Nossal GJV: The case history of Mr. T. I. - Terminal patient or still curable? Immunol Today 1980 (1):5–6CrossRefGoogle Scholar
  10. 10.
    Herberman RB: Multiple functions of natural killer cells, including immunoregulation as well as resistance to tumor growth. Concepts Immunopathol 1985 (1): 96: 118PubMedGoogle Scholar
  11. 11.
    Cavallo F, Riccardi C, Forni M, Di Pierro F, Soleti A, Giovarelli M, Novelli F and Forni G: Does the homing pattern of human malignant lymphoblasts in immunosuppressed nude mice depend on natural killer cells only? J Immunol Res 1991(3):163–168Google Scholar
  12. 12.
    Philips JH and Lanier LL: Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986 :814–825Google Scholar
  13. 13.
    Mule JJ, Shu S, Schwarz SL and Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984 (225): 1487: 1490Google Scholar
  14. 14.
    Mule JJ, Yang JC and Lafreniere R: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by systemic administration of high dose recombinant interleukin-2. J Immunol 1987 (139):285–291Google Scholar
  15. 15.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory JL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM: Observations on the systemic administration of autologous lymphokine-actived killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 1985 (313):1485–1492PubMedCrossRefGoogle Scholar
  16. 16.
    Mertelsmann R (ed) Lymphoematopoietic Growth Factors in Cancer Therapy. European School of Oncology Monograph Series. Springer-Verlag, Berlin 1990 pp 37–46Google Scholar
  17. 17.
    Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986 (223):1318–1321Google Scholar
  18. 18.
    Rosenberg SA, Packard BS, Aebersold PM, Solomon P, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp AA, Simpson C, Carter C, Bock S, Schwartzetruber D, Wei JP and White DE: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988 (318):1676–1680CrossRefGoogle Scholar
  19. 19.
    Anichini A, Fossati G and Parmiani G: Heterogeneity of clones from human metastatic melanoma detected by autologous cytotoxic T-lymphocytes clones. J Exp Med 1986 (163):215–220PubMedCrossRefGoogle Scholar
  20. 20.
    Rivoltini L, Gambacorti-Passerini C, Squadrelli- Saraceno M, Grosso Ml, Cantu’ G, Molinari R, Orazi A and Parmiani G: In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res 1990 (50):5551–5557PubMedGoogle Scholar
  21. 21.
    Van Der Eynde B, Hainaut P, Herin M, Knuth A, Lemoine C, Weinants P, Van Der Brüggen P, Fauchet R and Boon T. Presence of a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 1989 (44):634–640Google Scholar
  22. 22.
    Forni G and Santoni A: Immunogenicity of non- immunogenic tumors. J Biol Resp Modif 1984 (3):128–131Google Scholar
  23. 23.
    Smith KA: Cytokines in the nineties. Eur Cytokine Net 1990 (1):7–13Google Scholar
  24. 24.
    Novelli F, Giovarelli M, Reber-Liske R, Virgallita G, Garotta G and Forni G: Blockade of physiologically secreted interferon-gamma inhibits human T-lymphocytes and NK activation. J Immunol 1991 (147):1445–1452PubMedGoogle Scholar
  25. 25.
    Mitchison NA: Immunologic approach to cancer. Transplant Proc 1970 (2):92–103PubMedGoogle Scholar
  26. 26.
    Forni G, Fujiwara H, Martino F, Hamaoka T, Jemma C, Caretto P and Giovarelli M: Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lympokines for experimental and clinical immunotherapy. Cancer Met Rev 1989 (7):289–295CrossRefGoogle Scholar
  27. 27.
    Beard D, Murphy G, Maguire HC Jr and Mastrangelo MJ: Immunization with haptenized autologous tumor cells induces inflammation of human melanoma mestastases. Cancer Res 1991 (51):2731–2734Google Scholar
  28. 28.
    Colizzi V, Malkowsky M, Lang G and Asherson GL: In vivo activity of interleukin-2: conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by injection of interleukin-2. Immunology 1985 (56):653–659PubMedGoogle Scholar
  29. 29.
    Malkowsky M, Medawar PB, Thatcher DR, Toy J, Hunt R, Rayfield LS and Dore C: Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate. Proc Natl Acad Sci USA 1984 (83):536–538Google Scholar
  30. 30.
    Colizzi V, Malkowsky M, Lang G and Asherson GL: In vivo activity of interleukin-2: conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by injection of interleukin-2. Immunology 1985 (56):653–659PubMedGoogle Scholar
  31. 31.
    Kawamura H, Rosenberg SA and Berzofsky JA: Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Esp Med 1985 (162):381–385CrossRefGoogle Scholar
  32. 32.
    McCune OS Marquis DM: Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 1990 (50):1212–1215PubMedGoogle Scholar
  33. 33.
    Forni G, Giovarelli M and Santoni A: Lymphokine- activated tumor inhibition in vivo. I.The local administration of interlelukin 2 triggers nonreactive lymphocytes from tumor bearing mice to inhibit tumor growth. J Immunol 1985 (134):1305–1311PubMedGoogle Scholar
  34. 34.
    Bosco MC, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L and Forni G: Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990 (145):3136–3143PubMedGoogle Scholar
  35. 35.
    Musiani P, De Campora P, Valitutti S, Castellino F, Calearo CV, Jemma C, De Stefani A and Forni G: Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. J Biol Resp Modif 1989 (8):571–578Google Scholar
  36. 36.
    Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C Forni G: Treatment of recurrent squamous cell carcinoma of head and neck with low doses of Interleukin-2 (IL-2) injected perilymphatically. Cancer 1988 (62):2482–2490PubMedCrossRefGoogle Scholar
  37. 37.
    Forni G, Giovarelli M, Jemma C, Bosco MC, Carette P, Modesti A, Santoni A, Forni M, Cortesina G, De Stefani A, Cavallo GP, Galeazzi E, Musiani P, De Campora E, Valitutti S, Castellino F, Calearo CV, Fontana G Sesia G: Perilymphatic injections of cytokines: A new tool in active cancer immunotherapy. Experimental rationale and clinical findings. Ann 1st Super Sanit 1990 (26):397–410Google Scholar
  38. 38.
    Fontana G, Caccia P, Alladio F, Laudi M, Pigato M, Sesia G, Forni G and Giovarelli M: Interferon-gamma treatment of superficial and recurrent bladder carcinoma. Fase one study. In: Therapeutica Prog Urol Cancer. Alan Liss Ine, New York 1989 pp 479–480Google Scholar
  39. 39.
    Giovarelli M, Cofano F, Vecchi A, Forni M, Landolfo S and Forni G: Interferon-activated tumor inhibition in vivo. Int J Cancer 1986 (37):141–147Google Scholar
  40. 40.
    Forni G, Musso T, Jemma C, Boraschi D, Tagliabue A and Giovarelli M: Lymphokine activated tumor inhibition (LATI) in mice: ability of a nonapeptide of the human lnterleukin-1 to recruit antitumor reactivity in recipient mice. J Immunol 1989 (142):712–720PubMedGoogle Scholar
  41. 41.
    Vaage J: Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res 1987 (47):4296–4298PubMedGoogle Scholar
  42. 42.
    Forni G, Giovarelli M, Santoni A, Modesti A and Forni M: Interleukin-2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 1987 (138):4033–4041PubMedGoogle Scholar
  43. 43.
    Forni G, Giovarelli M, Bosco MC, Caretto P, Modesti A and Boraschi D: Lymphokine activated tumor inhibition: combinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4, and interferon-gamma injected around tumor-draining lymph nodes. Int J Cancer 1989 (S4):62–65CrossRefGoogle Scholar
  44. 44.
    Tepper RI, Pattengale PK and Leder P: Murine lnterleukin-4 displays potent anti-tumor activity in vivo. Cell 1989 (57):503–512PubMedCrossRefGoogle Scholar
  45. 45.
    Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B and Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990 (60):397–403PubMedCrossRefGoogle Scholar
  46. 46.
    Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990 (172):1217–1224PubMedCrossRefGoogle Scholar
  47. 47.
    Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T and Sakata T: Exogenous expression of mouse interferon-gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989 (86):9456–9461PubMedCrossRefGoogle Scholar
  48. 48.
    Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Fodolfo M, Mavilio F and Parmiani G: Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991 (173):889–897PubMedCrossRefGoogle Scholar
  49. 49.
    Oppenheim JJ, Zachriae COC, Muhaida N and Matsushima R: Properties of the novel proinflammatory supergene of the cytokine family. Ann Rev Immunol 1991 (9):617–648CrossRefGoogle Scholar
  50. 50.
    Cavallo F, Gulino A, Vacca A, Scala G, Giovarelli M and Forni G: Interleukin-induced tumor immunogenicity. In: Whiteside T and Goldfarb RH (eds) Tumor Immunology: Basic Mechanisms and Prospects for Therapy. Marcel Dekker Ine, New York 1992 (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Federica Cavallo
    • 1
  • Mirella Giovarelli
    • 1
  • Francesco Novelli
    • 1
  • Guido Forni
    • 2
  1. 1.Institute of MicrobiologyUniversity of TurinItaly
  2. 2.Centre of Immunogenetics and HistocompatibilityTurinItaly

Personalised recommendations